Overview
Oligoastrocytoma, also known as mixed oligoastrocytoma or mixed glioma, is a rare brain tumor that historically was classified as containing both oligodendroglial and astrocytic tumor cell components. It falls under the broader category of diffuse gliomas and is classified under ICD-10 code C71.9 (malignant neoplasm of brain, unspecified). These tumors primarily affect the central nervous system, most commonly arising in the cerebral hemispheres, particularly the frontal and temporal lobes. Oligoastrocytomas were traditionally graded as either WHO grade II (low-grade) or WHO grade III (anaplastic oligoastrocytoma), with the anaplastic variant carrying a worse prognosis. Key symptoms depend on tumor location and size but commonly include seizures, headaches, cognitive changes, personality or behavioral alterations, focal neurological deficits such as weakness or speech difficulties, and increased intracranial pressure. Seizures are frequently the presenting symptom, particularly in lower-grade tumors. Some patients may experience nausea, vomiting, or visual disturbances as the tumor grows and exerts mass effect on surrounding brain structures. It is important to note that the 2016 and 2021 WHO Classifications of Tumors of the Central Nervous System have largely eliminated oligoastrocytoma as a distinct diagnostic entity. Advances in molecular diagnostics, particularly IDH mutation status and 1p/19q codeletion testing, now allow most previously diagnosed oligoastrocytomas to be reclassified as either oligodendrogliomas (IDH-mutant, 1p/19q-codeleted) or astrocytomas (IDH-mutant, non-codeleted). Treatment typically involves a combination of maximal safe surgical resection, radiation therapy, and chemotherapy (often with temozolomide or PCV regimen consisting of procarbazine, lomustine, and vincristine). Prognosis varies based on molecular profile, tumor grade, extent of resection, and patient age.
Also known as:
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
2 eventsOurotech, Inc.
University of California, San Diego
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Oligoastrocytoma.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Oligoastrocytoma at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Oligoastrocytoma.
Community
No community posts yet. Be the first to share your experience with Oligoastrocytoma.
Start the conversation →Latest news about Oligoastrocytoma
Disease timeline:
New recruiting trial: Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis
A new clinical trial is recruiting patients for Oligoastrocytoma
New recruiting trial: Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)
A new clinical trial is recruiting patients for Oligoastrocytoma
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Oligoastrocytoma
What is Oligoastrocytoma?
Oligoastrocytoma, also known as mixed oligoastrocytoma or mixed glioma, is a rare brain tumor that historically was classified as containing both oligodendroglial and astrocytic tumor cell components. It falls under the broader category of diffuse gliomas and is classified under ICD-10 code C71.9 (malignant neoplasm of brain, unspecified). These tumors primarily affect the central nervous system, most commonly arising in the cerebral hemispheres, particularly the frontal and temporal lobes. Oligoastrocytomas were traditionally graded as either WHO grade II (low-grade) or WHO grade III (anaplas
How is Oligoastrocytoma inherited?
Oligoastrocytoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Oligoastrocytoma typically begin?
Typical onset of Oligoastrocytoma is adult. Age of onset can vary across affected individuals.
Which specialists treat Oligoastrocytoma?
24 specialists and care centers treating Oligoastrocytoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.